Geller Biopharm Inc. Represents Amunix for Merck License

Jan 3, 2019
1 min read

Amunix entered a licensing agreement with Merck for therapeutics using its proprietary protease-triggered immune-activator platform, with Geller Biopharm involved as advisor.

Originally listed in the Pickwick Capital Partners News archive. This migration copy uses a concise summary rather than the complete original article text.

Recent Posts

See All

Another insightful market perspective from John B. Levy & Company, Stuck in Second Gear, examines persistently elevated interest rates and their impact on commercial real estate financing, acquisition

Congratulations to Hummingbird Bioscience on winning the Asia Pacific Trailblazer Award at the 2026 Nebius AI Discovery Awards

Hummingbird Bioscience received the Asia Pacific Trailblazer Award at the 2026 Nebius AI Discovery Awards for its work applying artificial intelligence to biotherapeutic discovery.

Another insightful commentary from Cedars Hill Group, CHG Issue #229, The Return of the Wrecking Ball, examines the return of dollar strength, shifting liquidity conditions, and their impact on mar...

Cedars Hill Group reviews renewed U.S. dollar strength, changing liquidity conditions, and the resulting implications for markets, artificial intelligence, commercial real estate, and geopolitics.